PRAX•benzinga•
Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate
Summary
Praxis Precision Medicines' ulixacaltamide study for essential tremor faces setback as IDMC recommends stopping for futility. Topline results expected in Q3 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 3, 2025 by benzinga